Wire flash
FinanceOpko Health surges 33% on Q2 beat, raised FY revenue guidance
Editorial responsibility
- No named human review is recorded for this page.
- Source reporting is collected, normalized, translated or condensed automatically when needed.
- Automatically published source-backed update
Opko Health (NASDAQ: OPK) saw its stock price surge over 33% on Tuesday following a well-received quarterly earnings report. The company reported Q2 2026 revenue of $163.5 million, a 4% year-over-year increase, beating analyst consensus of $131 million. Net loss narrowed significantly to $8.4 million ($0.01 per share) from over $148 million a year ago, also beating estimates of a $0.08 per share loss. The pharmaceuticals segment drove growth with revenue rising to $89 million, boosted by higher sales volumes and a $29.4 million licensing gain. Diagnostics revenue declined to $74.5 million, partly due to the divestiture of oncology assets in September 2025. Opko raised its full-year 2026 revenue guidance to $560-585 million, up from the prior $530-560 million range and above analyst consensus of $537 million. The article notes the company appears leaner after shedding its oncology business and may approach profitability soon.
Source report
By Eric Volkman, The Motley Fool
Opko Health (NASDAQ: OPK) saw its stock price surge more than 33% on Tuesday, following a well-received quarterly earnings report that exceeded analyst expectations on both trailing results and annual guidance.
Major Improvements
Opko released its second-quarter results after market close on Monday. Key highlights include:
- Revenue: $163.5 million, up 4% year over year
- Net loss: $8.4 million ($0.01 per share), a significant improvement from the year-ago deficit of over $148 million
Both figures substantially surpassed analyst consensus estimates, which had projected revenue of just over $131 million and a net loss of $0.08 per share.
Pharmaceuticals Segment
The company's pharmaceuticals business showed strong improvement during the quarter:
- Revenue rose to $89 million, up from under $56 million in Q2 2025
- Growth attributed to higher sales volumes in certain markets
- Included a significant $29.4 million gain from a licensing deal
Diagnostics Segment
Revenue in the diagnostics business declined to $74.5 million, compared to $101.1 million in the year-ago period. However, the prior-year figure included approximately $25 million in sales from oncology assets, which were divested in September 2025.
Updated Guidance
Opko raised its full-year 2026 revenue guidance:
- New forecast: $560 million to $585 million
- Previous forecast: $530 million to $560 million
- Analyst consensus: Just under $537 million
The company appears to be operating as a leaner, more focused organization following the divestiture of its oncology business. The substantial guidance increase is an encouraging sign, and the company may approach profitability in the near term.
This article was written by Eric Volkman and originally published by The Motley Fool.
Source
Yahoo FinanceWestern
Part of this Story
Opko Health Stock Surges 33% on Strong Q2 Earnings and Raised Guidance